Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
Clinicians must be cautious when interpreting genomic reports. A 'negative' result doesn't confirm the absence of a mutation; it only means the specific test, with its inherent limitations like an inability to detect copy number alterations, did not identify it. This distinction is critical for accurate diagnosis.
Related Insights
While liquid biopsies are a valuable, less invasive tool, a negative result is inconclusive for ruling out actionable mutations in NSCLC. It may simply mean the tumor isn't shedding enough DNA. Therefore, a negative liquid biopsy should never be the final word; it must be followed by a tissue biopsy to ensure patients don't miss out on targeted therapies.
Standard Next-Generation Sequencing (NGS) reports often just state "MET amplification" without a specific copy number. To make informed treatment decisions with MET inhibitors, clinicians must proactively contact the testing company's molecular pathology department to obtain this crucial, unlisted data point.
The technology and breadth of molecular testing panels for GIST are rapidly evolving. A patient whose tumor tested negative for driver mutations in the past should be considered for re-testing with current, broader panels. This may uncover previously undetectable alterations like FGFR translocations and open up new treatment options.
Even a highly specific liquid biopsy test will produce many false positives in the general population. This is a mathematical certainty dictated by Bayes' theorem: when the 'prior probability' (the base rate of cancer) is very low, most positive signals will be statistical noise, not actual disease.
A negative liquid biopsy (ctDNA) result for HER2 amplification does not prove a patient is HER2-negative. The test's sensitivity is limited by tumor fraction in the blood. While a positive ctDNA result is highly specific and trustworthy, a negative result is simply 'not detected' and requires a tissue biopsy to definitively determine HER2 status for treatment decisions.
The success of Next-Generation Sequencing (NGS) is highly dependent on sample quality. Samples older than three years have degraded DNA. Furthermore, low tumor content, common in prostate cancer bone biopsies or plasma samples, makes it difficult to reliably detect the copy number changes required for analyses like LOH scores.
For critical driver mutations like ROS1 and ALK fusions, relying solely on DNA-based Next-Generation Sequencing (NGS) is insufficient. A study showed that a significant portion of these fusions are only detectable via RNA sequencing. Clinicians must verify that RNA analysis was included in NGS reports to avoid missing effective targeted therapies for one in five potential patients.
In patients with liver metastases, a low tumor fraction can cause false-negative liquid biopsy (ctDNA) results. Clinicians recommend obtaining a tissue biopsy to confirm the absence of targetable mutations and ensure concordance, preventing misinformed treatment decisions based on potentially inaccurate ctDNA.
Experts warn against over-interpreting a single negative ctDNA test after surgery, clarifying that these patients still face a significant 25-30% risk of recurrence. The biomarker's true prognostic power comes from serial testing that shows a patient remains persistently negative over time.
Different commercial and institutional molecular testing platforms can produce disparate results for the same tumor specimen. This variability in tests for markers like MGMT promoter methylation or 1p19q codeletion can lead to incorrect diagnoses and misguided treatment plans for glioma patients.